References

rsp

Научно-практическая ревматология

Rheumatology Science and Practice

1995-44841995-4492

IMA-PRESS, LLC

10.14412/1995-4484-2015-1-17

rsp-2136

Research Article

Статьи

Articles

Проект рекомендаций по лечению ревматоидного артрита Общероссийской общественной организации «Ассоциация ревматологов России» – 2014 (часть 1)

PROJECT: RECOMMENDATIONS ON TREATMENT OF RHEUMATOID ARTHRITIS DEVELOPED BY ALL-RUSSIAN PUBLIC ORGANIZATION «ASSOCIATION OF RHEUMATOLOGISTS OF RUSSIA» – 2014 (PART 1)

Насонов

Е. Л.

Nasonov

E. L.

sokrat@irramn.ru

Мазуров

В. И.

Mazurov

V. I.

Каратеев

Д. Е.

Karateev

D. E.

Лукина

Г. В.

Lukina

G. V.

Жиляев

Е. В.

Zhilyaev

E. V.

Амирджанова

В. Н.

Amirdzhanova

V. N.

Муравьев

Ю. В.

Muraviyov

Yu. V.

Чичасова

Н. В.

Tchichasova

N. V.

ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой; 115522, Россия, Москва, Каширское шоссе, 34А Кафедра ревматологии ГБОУ ВПО «Первый Московский медицинский университет им. И.М. Сеченова» Минздрава России; 119991, Россия, Москва, ул. Трубецкая, 8, стр. 2РоссияV.A. Nasonova Research Institute of Rheumatology; 34A, Kashirskoe Shosse, Moscow, 115522, Russia Rheumatology Department I.M. Sechenov First Moscow Medical University; 8, build. 2, Trubetskaya St., Moscow, 119991, RussiaRussian Federation

ГБОУ ВПО «Северо-Западный государственный медицинский университет им. И.И. Мечникова»; 191015, Россия, Санкт-Петербург, ул. Кирочная, 41РоссияI.I.Mechnikov North-Western State Medical University; 41, Kirochnaya St., St.Petersburg, 191015, RussiaRussian Federation

ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой; 115522, Россия, Москва, Каширское шоссе, 34АРоссияV.A. Nasonova Research Institute of Rheumatology; 34A, Kashirskoe Shosse, Moscow, 115522, RussiaRussian Federation

ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой; 115522, Россия, Москва, Каширское шоссе, 34А Городская клиническая больница No1 им. Н.И. Пирогова; 117049, Россия, Москва, Ленинский проспект, 8РоссияV.A. Nasonova Research Institute of Rheumatology; 34A, Kashirskoe Shosse, Moscow, 115522, Russia N.I.Pirogov Municipal Clinical Hospital No1; 8, Leninsky prospekt, Moscow, 117049, RussiaRussian Federation

Городская клиническая больница No1 им. Н.И. Пирогова; 117049, Россия, Москва, Ленинский проспект, 8РоссияN.I.Pirogov Municipal Clinical Hospital No1; 8, Leninsky prospekt, Moscow, 117049, RussiaRussian Federation

Кафедра ревматологии ГБОУ ВПО «Первый Московский медицинский университет им. И.М. Сеченова» Минздрава России; 119991, Россия, Москва, ул. Трубецкая, 8, стр. 2РоссияRheumatology Department I.M. Sechenov First Moscow Medical University; 8, build. 2, Trubetskaya St., Moscow, 119991, RussiaRussian Federation

2015

22102015

535s117

2015

Насонов Е.Л., Мазуров В.И., Каратеев Д.Е., Лукина Г.В., Жиляев Е.В., Амирджанова В.Н., Муравьев Ю.В., Чичасова Н.В.

Nasonov E.L., Mazurov V.I., Karateev D.E., Lukina G.V., Zhilyaev E.V., Amirdzhanova V.N., Muraviyov Y.V., Tchichasova N.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://rsp.mediar-press.net/rsp/article/view/2136

Представлены новые рекомендации Общероссийской общественной организации «Ассоциация ревматологов России» (АРР) по лечению ревматоидного артрита (РА), адаптирующие современную концепцию фармакотерапии этого заболевания – «Лечение до достижения цели». Согласно рекомендациям основная цель фармакотерапии РА – достижение ремиссии (или низкой активности) заболевания. Для реализации этой цели терапия базисными противовоспалительными препаратами (БПВП) должна назначаться всем пациентам с РА как можно раньше, а эффективность терапии – тщательно контролироваться и модифицироваться в зависимости от активности заболевания. Акцентируется внимание на применении метотрексата (МТ) в качестве «золотого стандарта» фармакотерапии РА и ключевого компонента стратегии «Лечение до достижения цели». Раннее назначение МТ (в том числе в форме для подкожного введения) должно стать обязательным компонентом лечения РА на всех стадиях болезни. При недостаточной эффективности или плохой переносимости МТ (включая подкожную форму препарата) или комбинированной терапии МТ и стандартными БПВП следует назначить генно-инженерные биологические препараты (ГИБП), включающие ингибиторы фактора некроза опухоли α, ингибиторы рецепторов интерлейкина 6 (тоцилизумаб), анти-В-клеточные препараты (ритуксимаб) и блокаторы активации Т-лимфоцитов (абатацепт). Терапия тофацитинибом (ингибитор JAK) оправдана у пациентов, резистентных к стандартным БПВП и ГИБП. Все ГИБП и тофацитиниб предпочтительнее применять в комбинации с МТ (или другими БПВП).

Authors report new recommendations of All-Russian Public Organization «Association of Rheumatologists of Russia» (ARR) on treatment of rheumatoid arthritis (RA), which adapts contemporary concept accepted in the respective field of pharmacotherapy known as «Treat to Target». According to it, the main objective of RA pharmacotherapy is a remission (or low disease activity). To achieve it, disease modifying anti-rheumatic drugs (DMARD) should be administered to all RA patients as early as possible, with efficacy monitoring and therapy correction according to the disease activity. Special attention has been paid to the use of methotrexate (MTX) as «the gold standard» of RA pharmacotherapy and the key component of «Treat to Target» strategy. Early MTX administration (including subcutaneous injections) should become an obligatory component of RA treatment at all stages of the disease. If MTX is not efficient or not well tolerated (including subcutaneous form of the drug) as monotherapy or combined with conventional DMARD, biological agents should be used. Those include TNFα inhibitors, antagonist of interleukin-6 receptor (Tocilizumab), anti-B-cell drugs (Rituximab) and agents blocking T-cell activation (Abatacept). Tofacitinib therapy (JAK inhibitor) is indicated in patients who are resistant to conventional DMARDs and biologics. All biologics and Tofacitinib are more effective in combination with MTX (or other DMARD).

ревматоидный артритстратегия «Лечение до достижения цели»базисные противовоспалительные препаратыгенно-инженерные биологические препаратыметотрексат

rheumatoid arthritis«Treat to Target»disease modifying anti-rheumatic drugsbiologicsmethotrexate

References1

Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. Москва: ГЭОТАР-Медиа; 2008. С. 290-331. [Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In: Revmatologiya. atsional’noe rukovodstvo [Rheumatology. National Guide]. Nasonov EL, Nasonova VA, editors. Moscow: PEOTAR-media; 2008. P. 290-331.]

McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. New Engl J Med. 2012;365:2205-19. DOI: 10.1056/NEJMra1004965.

Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370:1861-71. DOI: 10.1136/annrheumdis-2011-201036.

Furst DE, Keystone EC, Braun J, et al. Update consensus statement on biological agents for the treatment of rheumatic disease, 2011. Ann Rheum Dis. 2012;71 (Suppl II):i2-i45. DOI: 10.1136/annrheumdis-2011-201036.

Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМА-ПРЕСС; 2013. [Nasonov EL, editor. Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biological preparations in treatment of rheumatoid arthritis]. Moscow: IMA-PRESS; 2013.]

Sokka T, Pincus T. Rheumatoid arthritis: strategy more important than agent. Lancet. 2009;374:430-2. DOI: 10.1016/S0140-6736(09)61432-X.

Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631-7. DOI: 10.1136/ard.2009.126532.

Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheumatic drugs. Ann Rheum Dis. 2010;69:964-75. DOI: 10.1136/annrheumdis-2013-204573.

Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with systemic and biological disease-modifying anti-rheumatic drugs: 2013. Ann Rheum Dis. 2014;73:492-509. DOI: 10.1136/annrheumdis-2013-204573.

Насонов ЕЛ, Каратеев ДЕ, Чичасова НВ. Рекомендации EULAR по лечению ревматоидного артрита - 2013: общая характеристика и дискуссионные проблемы. Научно- практическая ревматология. 2013;51(6):609-22. [Nasonov EL, Karateev DE, Chichasova NV. EULAR recommendations for the treatment of rheumatoid arthritis - 2013: general characteristics and disputable problems. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(6):609-22. (In Russ.)]. DOI: 10.14412/1995-4484-2013-609-22.

Aletaha D, Neogri T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria. An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569-81. DOI: 10.1002/art.27584.

Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63:573-86. DOI: 10.1136/annrheumdis-2013-204317.

Smolen JS, van der Heijde D, Machold KP, et al. Proposal for a new nomenclature of disease-modifying anti-rheumatic drugs. Ann Rheum Dis. 2014;73:3-5. DOI: 10.1136/annrheumdis-2013-204317.

Национальные рекомендации по лечению ревматоидного артрита, 2013 (проект). Доступ по ссылке: http://www.rheumatolog.ru/experts/national-guidelines [Natsional'nye rekomendatsii po lecheniyu revmatoidnogo artrita, 2013 (proekt) [National recommendations about treatment of rheumatoid arthritis, 2013 (project)]. Available from: http://www.rheumatolog.ru/experts/national-guidelines]

Насонов ЕЛ, редактор. Ревматология. Клинические рекомендации. Москва: ГЭОТАР-Медиа; 2010. 752 c. [Nasonov EL, editor. Revmatologiya. Klinicheskie rekomendatsii [Rheumatology. Clinical recommendations.]. Moscow: GEOTAR-Media; 2010. 752 p.]

Насонов ЕЛ, редактор. Лечение ревматоидного артрита. Клинические рекомендации. Москва: Алмаз; 2006. 118 с. [Nasonov EL, editor. Lechenie revmatoidnogo artrita. Klinicheskie rekomendatsii [Treatment of rheumatoid arthritis. Clinical recommendations]. Moscow: Almaz; 2006. 118 p.]

Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66:34-45. DOI: 10.1136/ard.2005.044354.

Luqmani R, Hennel S, Estrach C, et al.; British Society for Rheumatology, British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group. British Society for Rheumatology and british health professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years). Rheumatology (Oxford). 2006;45:1167-9. DOI: 10.1093/rheumatology/kel215a.

Luqmani R, Hennel S, Estrach C, et al.; British Society for Rheumatology (Oxford), British Health Professionals in Rheumatology (Oxford) Standards, Guidelines and Audit Working Group. British Society for Rheumatology (Oxford) and British Health Professionals in Rheumatology (Oxford) Guideline for the Management of Rheumatoid Arthritis (after the first two years). Rheumatology (Oxford). 2009;48:436-9. DOI: 10.1093/Rheumatology(Oxford)/key450a.

Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying ant rheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762-84. DOI: 10.1002/art.23721.

Singh JA, Furst D, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying anti-rheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64:625-39. DOI: 10.1002/acr.21641.

Bykerk VP, Akhavan P, Hazlewood GS, et al. Canadian Rheumatology (Oxford) Association Recommendations for Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs. J Rheumatol. 2012;39:1559-82. DOI: 10.3899/jrheum.110207.

National Institute for Clinical Excellence (NICE). Rheumatoid arthritis: The management of rheumatoid arthritis in adults. NICE guidelines [CG79]. 2009. [Internet. Accessed July 14, 2011.] Available from: http://www.nice.org.uk/nicemedia/pdf/CG79NICEGuideline.pdf

The Royal Australian College of General Practitioners. Clinical guidelines for diagnosis and management of early rheumatoid arthritis; 2008. [Internet. Accessed July 14, 2011.] Available from: http://www.healthnetworks.health.wa.gov.au/docs/Clinical_guidelines_Rheumatoid_Arthritis.pdf; http://www.racgp.org.au/guidelines musculoskeletaldiseases

Baecklund E, Forsblad d’Elia H, Turesson K. Guidelines for the pharmaceutical management of rheumatoid arthritis Swedish Society of Rheumatology. 2011. April 14. Available from: http://www.svenskreumatologi.se/index2.htm

Scottish Intercollegiate Guidelines Network (SIGN). Management of early rheumatoid arthritis: SIGN Publication No. 48 2000; [Internet. Accessed July 14, 2011.] Available from: http: //www. http://sign.ac.uk/guidelines/fulltext/48/index.html

GUIPCAR group. Update of cliniсal practice guidline for the management of rheumatoid arthritis in Spain. Madrid (Spain): Spanish Scociety of Rheumatology; 2011. 367 p.

Da Mota LMH, Cruz BA, Brenol CV, et al. 2012 Brazilian Society of Rheumatology Consensus for the treatment of rheumatoid arthritis. Rev Bras Reumatol. 2012;52:135-74.

Ataman S, Borman P, Evcik D, et al. Management of rheumatoid arthritis: consensus recommendations from the Turkish League Against Rheumatism. Turk J Rheumatol. 2011;26:273-94. DOI: 10.5606/tjr.2011.046.

Mok CC, Tam LS, Chan TH, et al. Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology. Clin Rheumatol. 2011;30:303-12. DOI: 10.1007/s10067-010-1596-y.

El Zorkany B, Alwahshi HA, Hammoudeh M, et al. Suboptimal management of rheumatoid arthritis in the Middle East and Africa: could the EULAR recommendations be the start of a solution? Clin Rheumatol. 2013;32:151-9. DOI: 10.1007/s10067-012-2153-7.

Fonseca JE, Bernardes M, Canhao H, et al. Portuguese guidelines for the use of biological agents in rheumatoid arthritis - October 2011 update. Acta Reumatol Port. 2011;36:385-8.

Gaujoux-Viala C, Gossec L, Cantagrel A, et al. Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis. Joint Bone Spain. 2014;81(4):287-97. DOI: 10.1016/j.jbspin.2014.05002.

Cardiel MH, Diaz-Borjon A, Vazquez del Mercado Espinosa M, et al. Update of the Mexican College of Rheumatology (Oxford) Guidelines for the Pharmacologic Treatment of Rheumatoid Arthritis. Reumatologia Clinica. 2014;19:227-40.

Wollenhaupt J, Albrecht K, Kruger K, Muller-Ladner U. The new 2012 German recommendations for treating rheumatoid arthritis. Z Rheumatol. 2013;72:6-9. DOI: 10.1007/s00393-012-1093-6.

Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid rthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis. 2013;72:64-71. DOI: 10.1136/annrheumdis-2011-201247.

Mierau M, Schoels M, Gonda G, et al. Assessing remission in clinical practice. Rheumatology (Oxford). 2007;46:975-9. DOI: 10.1093/rheumatology/kem007.

Smolen JS, Han C, van der Heijde D, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and TNFblockade. Ann Rheum Dis. 2009;68:823-37. DOI: 10.1136/ard.2008.090019.

Koevoets R, van der Heijde D. Being in remission or in low disease activity in rheumatoid arthritis: different meaning with the use of different composite scores. Arthritis Rheum. 2009;60(Suppl):957.

Aletaha D, Smolen JS. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. Arthritis Rheum. 2011;63:3702-11. DOI: 10.1002/art.30634.

Sakellariou G, Scire CA, Verstappen SM, et al. In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis. Ann Rheum Dis. 2013;72:245-9. DOI: 10.1136/annrheumdis-2012-201817.

Gartner M, Mandl P, Radner H, et al. Sonographic joint assessment in rheumatoid arthritis: Associations with clinical joint assessment in remission. Arthritis Rheum. 2013;65:2005-14. DOI: 10.1002/art38016.

Aletaha D, Landewe R, Karonitsch T, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis. 2008;67:1360-4. DOI: 10.1136/ard.2008.091454.

Klarenbeek NB, Koevoets R, van der Heijde DM, et al. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis. Ann Rheum Dis. 2011;70:1815-21. DOI: 10.1136/ard.2010.149260.

Scire CA, Lunt M, Marshall T, et al. Early remission is associated with improved survival in patients with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis. 2014;73:1677-82. DOI: 10.1136/annrheumdis-2013-203339.

Criswell LA, Such CL, Yelin EH. Differences in the use of second-line agents and prednisone for treatment of rheumatoid arthritis by rheumatologists and non-rheumatologists. J Rheumatol. 1997;24:2290.

Yelin EH, Such CL, Criswell LA, Epstein WV. Outcomes for persons with rheumatoid arthritis with a rheumatologist versus a non-rheumatologist as the main physician for this condition. Med Care. 1998;36:513-22. DOI: 10.1097/00005650-199804000-00007.

Ward MM, Leigh JP, Fries JF. Progression of functional disability in patients with rheumatoid arthritis. Associations with Rheumatology subspecialty care. Arch Intern Med. 1993;153:2229-37. DOI: 10.1001/archinte.1993.00410190069009.

Solomon DH, Bates DW, Panush RS, Katz JN. Costs, outcomes, and patient satisfaction by provider type for patients with rheumatic and musculoskeletal conditions: a critical review of the literature and proposed methodological standards. Ann Intern Med. 1997;127:52-60. DOI: 10.7326/0003-4819-127-1-199707010-00009.

Widdifield J, Bernatsky S, Paterson JM, et al. Quality care in seniors with new-onset rheumatoid arthritis: a Canadian perspective. Arthritis Care Res (Hoboken). 2011;63:53-7. DOI: 10.1002/acr.20304.

Bonafede MM, Fox KM, Johnson BH, et al. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study. Clin Ther. 2012;34:457-67. DOI: 10.1016/j.clinthera.2011.12.016.

Lahiri M, Morgan C, Symmons DPM, Bruce IN. Modifiable risk factors for RA: prevention, better than cure. Rheumatology (Oxford). 2012;51:499-512. DOI: 10.1093/rheumatology/ker299.

Sanberg ME, Bengtsson C, Kallberg H, et al. Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis. Ann Rheum Dis. 2013. DOI: 10.1136/annrheumdis-2013-205094.

Ellerby N, Mattey D, Packham J, et al. Obesity and comorbidity are independently associated with failure to achieve remission in patients with established rheumatoid arthritis. Ann Rheum Dis. 2014. DOI: 10.1136/annrheumdis-2014-206254.

De Pablo P, Chapple ILC, Buckley CD, Dietrich T. Periodontitis in systemic rheumatic disease. Nat Rev Rheumatol. 2009;68(5):218-24. DOI: 10.1038/nrrheum.2009.28.

Iversen MD, Brawerman M, Iversen CN. Recommendations and the state of the evidence for physicial activity interventions for adults with rheumatoid arthritis: 2007 to present. Int J Clin Rheumatol. 2012;7(5):489-503. DOI: 10.2217/ijr.12.53.

Whittle S, Colebatch A, Buchbinder R, et al. Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. Rheumatology (Oxford). 2012;51:1416-25. DOI: 10.1093/rheumatology/es032.

Каратеев АЕ, Яхно НН, Лазебник ЛБ и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. Москва: ИМА-ПРЕСС; 2009. 167 с. [Karateev AE, Yakhno NN, Lazebnik LB, et al. Primenenie nesteroidnykh protivovospalitel'nykh preparatov. Klinicheskie rekomendatsii [Application of nonsteroid antiinflammatory preparations. Clinical recommendations]. Moscow: IMA-PRESS; 2009. 167 p.]

Burmester G, Lanas A, Biasucci L, et al. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinion of multidisciplinar European expert panel. Ann Rheum Dis. 2010;70(5):818-22. DOI: 10.1136/ard.2010.128660.

Gorter SL, Bijlsma JW, Cutolo M, et al. Current evidence for management of rheumatoid arthritis with glucocorticoids: systemic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69:1010-4. DOI: 10.1136/ard.2009.127332.

Hoes JN, Jacobs JWG, Boers M, et al. EULAR evidence based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66:1560-7. DOI: 10.1136/ard.2007072157.

Da Silva JAP, Jacobs JWG, Kirwan JR, et al. Low-dose glucocorticoid therapy in rheumatoid arthritis. A review on safety: published evidence and prospective trial data. Ann Rheum Dis. 2006;65:285-93. DOI: 10.1136/ard.2005.038638.

Donahue KE, Gartlehner G, Jonas DE, et al. Systemic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med. 2008;148:124-34. DOI: 10.7326/0003-4819-148-2-200801150-00192.

Gaujoux-Viala C, Smolen JS, Landewe R, et al. Current evidence for management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systemic literature review informing EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69:1004-9. DOI: 10.1136/ard.2009.127225.

Gaujoux-Viala C, Nam JL, Ramiro S, et al. Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib - a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:510-5. DOI: 10.1136/annrheumdis-2013-204588.

Nam JL, Winthrop KL, van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis. 2010;69:976-86. DOI: 10.1136/ard.2009.126573.

Nam JL, Ramiros S, Gaujoux-Viala C, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:516-28. DOI: 10.1136/annrheumdis-2013-204577.

Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs - a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:529-35. DOI: 10.1136/annrheumdis-2013-204575.

Vliet Vlielan TPM. Non-drug care for RA - is the era of evidence-based practice approaching? Rheumatology (Oxford). 2007;46:1397-1404. DOI: 10.1093/Rheumatology/key149.

Oldfield V, Felson DT. Exercise therapy and orthotic devices in rheumatoid arthritis: evidence-based review. Curr Opin Rheumatol. 2008;20:353-9. DOI: 10.1097/BOR.0b013e3282fd17df.

Finckh A, Liang MH, Mugica C, et al. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Care Res. 2006;15:864-72. DOI: 10.1002/art.22353.

Nies JAB, Krabben A, Schoones JW, et al. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis. 2014;73:861-70. DOI: 10.1136/annrheumdis-2012-203130.

Van der Linden MP, le Cessie S, Raza K, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 2019;62:3537-46. DOI: 10.1002/art.27692.

Aletaha D, Funovits J, Keystone EC, et al. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum. 2007;56:3226-35. DOI: 10.1002/art.22943.

Radner H, Neogi T, Smolen J, Aletaha D. Perfomance of the 2010 ACR/EULAR classifications criteria for rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2014;73:114-23. DOI: 101136/annrheumdis-2013-20328.

Sakellariou G, Scire CA, Zambon A, Caporali R. Perfomance of the 2010 classification criteria for rheumatoid arthritis: a systemic literature review and meta-analysis. PLOS ONE. 2013;8e56528.

Knevel R, Schoels M, Huizinga TWJ, et al. Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying anti-rheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69:987-94. DOI: 10.1136/ard.2009.126748.

Schipper LG, van Hulst LTC, Grol R, et al. Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. Rheumatology (Oxford). 2010;49:2154-64. DOI: 10.1093/Rheumatology/keq195.

Kuriya B, Arkema EV, Bykerk VP, Keystone EC. Efficacy of initial methotrexate monotherapy versus combination therapy with biological agent in early rheumatoid arthritis: a metaanalysis of clinical and radiographic remission. Ann Rheum Dis. 2010;69:1298-304. DOI: 10.1136/ard2009.118307.

Katchamart W, Trudeau J, Phumethum V, et al. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2009;68:1105-12. DOI: 10.1136/ard.2008.099861.

Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systemic literature research. Ann Rheum Dis. 2009;68:1100-4. DOI: 10.1136/ard.2008.093690.

Visser K, Katchhamart W, Losa E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systemic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiatiive. Ann Rheum Dis. 2009;68:1086-93. DOI: 10.1136/ard.2008.094474.

Todoerti M, Maglione W, Bernero E, et al. Systemic review of 2008-2012 literature and update of recommendations for the use of methotrexate in rheumatic disease, with focus one rheumatoid arthritis. Rheumatismo. 2013;65:207-18.

Van Dongen H, vam Aken J, Lard LR, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis. A double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007;56:1424-32. DOI: 10.1002/art.22525.

Kudo-Tanaka E, Matsushita M, Tsuji S, et al. Prevention of development of rheumatoid arthritis (RA) in patients with undifferentiated arthritis (UA) by very early therapeutic interventioin of methotrexate (MTX). Ann Rheum Dis. 2013;72(Suppl 3):244. DOI: 10.1136/annrheumdis-2013-eular.763.

Heimans L, Wevers-de Boer K, Visser K, et al. A two-step treatment strategy trial in patients with early arthritis aimed achieving remission: the IMPROVED study. Ann Rheum Dis. 2013;73(7):1356-61. DOI: 10.1136/annrheumdos-2013-203243.

Emery P, Durez P, Dougados M, et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis. 2010;69:510-6. DOI: 10.1136/ard.2009.119016.

De Jong PH, Hazes JM, Barenndregt PJ, et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis. 2013;72(1):72-8. DOI: 10.1136/annrheumdis-2011-201162.

De Jong PHPD, Hazes JM, Luime JJ, et al. Randomized comparison of triple DMARD therapy with methotrexate monotherapy. Ann Rheum Dis. 2013;72(Suppl 3):113. DOI: 10.1136/annrheumdis-2013-eular.382.

Villeneuve E, Nam JL, Hensor E, et al. Preliminary results of a multicenter randomized controlled trial of etanercept and methotrexate to induce remission in patients with newly diagnosed inflammatory arthritis. Arthritis Rheum. 2011;63 (Suppl 10):2465.

Vermeer M, Kuper HH, Hoekstra M, et al. Implementation of a Threat-to-Target Strategy in very early rheumatoid arthritis. Results of the Dutch Rheumatoid Arthritis Monitoring Remission Induction Cohort Study. Arthritis Rheum. 2011;63:2865-72. DOI: 10.1002/art.30494.

Vermeer M, Kuper HH, Bernelot Moens HJ, et al. Sustained beneficial effects of a protocolized Treat-to-Target strategy in very early rheumatoid arthritis: three-year results of the Dutch Rheumatoid Arthritis Monitoring Remission Induction Cohort. Arthritis Care Res. 2013;65:1219-26. DOI: 10.1992/acr.21984.

Bosello S, Fedele AL, Peluso G, et al. Very early rheumatoid arthritis is the major predictor of major outcome: clinical ACR remission and radiographic non-progression. Ann Rheum Dis. 2011;70:1292-5. DOI: 10.1136/ard.2010.142729.

Baker M, Jacobs JWG, Welsing PMJ, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis. Ann Intern Med. 2012;156;329-39. DOI: 10.7326/0003-4819-156-5-201203060-00004.

Montecucco C, Todoerti M, Sakellariou G, et al. Low-dose oral prednisolone improves clinical and ultrasonography remission rates in early rheumatoid arthritis: results of a 12- month open-label randomized study. Arthritis Res Ther. 2012;14:R112. DOI: 10.1186/ar3838.

St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50:3432-43. DOI: 10.1002/art.20568.

Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study - a multicenter, randomized, doubleblind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37. DOI: 10.1002/art.21519.

Takeuchi T, Yamanaka H, Ishiguro N, et al. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for prevention of joint damage in Japanese patients with early rheumatoid arthritis; the HOPEFUL 1 study. Ann Rheum Dis. 2013;73(3):536-43. DOI: 10.1136/annrheumdis-2012-202433.

Bejarano V, Quinn M, Conaghan PG, et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in the patients with early rheumatoid arthritis. Arthritis Rheum. 2008;59:1467-74. DOI: 10.1002/art.24106.

100

Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT-HARD, an investigator-initiated study. Ann Rheum Dis. 2013;72:844-50. DOI: 10.1136/annrheumdis-2012-201612.

101

Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate- naive patients with active rheumatoid arthritis: twentyfour- week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009;60:2272-83. DOI: 10.1002/art.24638.

102

Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active early, moderate to severe rheumatoid arthritis (COMET): a randomized, double-blind, parallel treatment trial. Lancet. 2008;372:375-82. DOI: 10.1016/S0140-6736(08)61000-4.

103

Emery P, Breedveld F, van der Heijde D, et al. Two-year clinical and radiographic results with combination etanerceptmethotrexate therapy versus monotherapy in early rheumatoid arthritis. A two-year, double-blind, randomized study. Arthritis Rheum. 2010;62:674-82. DOI: 10.1002/art.272668.

104

Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009;68:1870-7. DOI: 10.1136/ard.2008.101121.

105

Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011;70:39-46. DOI: 10.1136/ard.2010.137703.

106

Burmester GR, Rigby W, van Vollenhoven R, et al. Tocilizumab (TCZ) in combination and monotherapy versus methotrexate (MTX) in MTX-naive patients (pts) with early rheumatoid arthritis (RA): clinical and radiographic outcomes from a randomised, placebo-controlled trial. Ann Rheum Dis. 2013;72(Suppl):OP041. DOI: 10.1136/annrheumdis-2013-eular.246.

107

Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early arthritis: a randomized trial. Lancet. 1999;353:1568-73. DOI: 10.1016/S0140-6736(98)08513-4.

108

Korpela M, Laasonen L, Hannonen P, et al. Retardation of joint damage by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FINRACo study. Arthritis Rheum. 2004;50:2072-81. DOI: 10.1002/art.20351.

109

Rantalaiho V, Korpela M, Hannonen P, et al. The good initial response to therapy with a combination of traditional diseasemodifying antirheumatic drugs is sustained over time. The eleven-year results of the Finish rheumatoid arthritis combination therapy trial. Arthritis Rheum. 2009;60:1222-31. DOI: 10.1002/art.24447.

110

Rantalaiho V, Korpela M, Laasonen L, et al. Early combination disease-modygying antirheumatic drug therapy anf tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther. 2010;12:R122. DOI: 10.1186/ar3060.

111

Hertland ML, Stengaard-Petersen K, Junker P, et al. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethason in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, doubleblind, parallel-group, placebo-controlled study. Arthritis Rheum. 2006;54:1401-9. DOI: 10.1002/art.21796.

112

Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study). Arthritis Rheum. 2005;52:3381-90. DOI: 10.1002/art.21405.

113

Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis. Ann Intern Med. 2007;146:406-15. DOI: 10.7326/0003-4819-146-6-200703200-00005.

114

Markusse IM, Akdemir G, van den Broek M, et al. 10 year of treat-to-target therapy in rheumatoid arthritis patients (the BeST study): clinical and radiological outcome. Arthritis Rheum. 2013;65 (Suppl):S62.

115

Leirisalo-Repo M, Kautinen H, Laasonen L, et al. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2 year results from an investigator-initiated, randomized, double-blind, placebo-controlled study (the NEORACo Study). Ann Rheum Did. 2013;72:851-7. DOI: 10.1136/annrheumdis-2012-201365.

116

Rantalaiho V, Kautianen H, Korpela M, et al. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-tear follow-up results of a randomized clinical trial, the NEO-RACo trial. Ann Rheum Dis. 2013. DOI: 10.1136/annrheumdis-2013-203497.

117

Horslev-Petersen K, Hertland ML, Junker P, et al. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA study; an investigator-initiated, randomized, double-blind, parallel-group, placebo-controlled trial. Ann Rheum Dis. 2014;73:654-61. DOI: 10.1136/annrheumdis-2012-202735.

118

Nam JR, Villeneuve E, Hensor EME, et al. Remission induction comparing infliximab and high-dose intravenous steroids, followed by treat-to target: a double-blind, randomized, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis. 2014;73:75-85. DOI: 10.1136/annrheumdis-2013-2034440.

119

Den Uyl D, ter Wee M, Boers M, et al. A non-inferiority trial of an attenuated combination strategy («COBRA-light») compared to the original COBRA strategy: clinical results after 26 weeks. Ann Rheum Dis. 2014;73(6):1071-8. DOI: 10.1136/annrheumdis-2012-202818.

120

Soubrier M, Puechal X, Sibilia J, et al. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology (Oxford). 2009;48:1429-34. DOI: 10.1093/rheumatology/kep261.

121

Yamanaka H, Ishigurp N, Takeuchi T, et al. Recovery of clinical but not radiographic outcome by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial. Rheumatology (Oxford). 2014. DOI: 101093/Rheumatology(Oxford)/key465.

122

Moreland LW, O’Dell JR, Paulus H, et al. TEAR: treatment of early aggressive RA; A randomized, double-blind, 2-year trial comparing immediate triple DMARD versus MTX plus etanercept to step-up from initial MTX monotherapy. Arthritis Rheum. 2012;64:2824-35. DOI: 10.1002/art.34498.

123

O’Dell JR, Curtis JR, Mikuls TR, et al.; TEAR trial investigators. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis. Results from a two-year randomized, double-blind trial. Arthritis Rheum. 2013;65:1985-94. DOI: 10.1002/art.38012.

124

O’Dell, JR, Mikuls TR, Taylor TH, et al.; CSP 551 RACAT investigators. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013;369:307-18. DOI: 10.1056/NEJMoa1303006.

125

Van Vollenhoven RF, Geborek P, Forslind K, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomized, non-blinded, parallelgroup Swefot trial. Lancet. 2012;379:1712-20. DOI: 10.1016/S0140-6736(12)60027-0.

126

De Cock D, Meyfroidt S, Joly J, et al. For remission induction with glucocorticoid bridging, methotrexate monotherapy is as effective as combination with other DMARDs, with fewer reported side effects: 4-month primary outcome of CareRa, a randomized induction strategy and treated-to-target trial n early RA. Arthritis Rheum. 2013;14 (abstract 14).

127

Pavy S, Constantin A, Pham T, et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine. 2006;73:388-95.

128

Katchamart W, Bourre-Tessier J, Donka T, et al. Canadian recommendation for use methotrexate in patients with rheumatoid arthritis. J Rheumatol. 2010;37:1422-30. DOI: 10.3894/jrheum/090978.

129

Tornero Molina J, Garcia FJB, Alen JC, et al. Recommendations for the use of methotrexate in rheumatoid arthritis: up and down scaling of the dose and administration route. Reumatologia Clinica.

130

;pii:S1699-258X(14)00059-X. DOI: 10.1016/j.reuma.2014.02.012.

131

Насонов ЕЛ. Лечение ревматоидного артрита 2012: место метотрексата. Научно-практическая ревматология. 2012;51(приложение 3):1-24. [Nasonov EL. Treatment of rheumatoid arthritis 2012: methotrexate place. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;51(Suppl 3):1-24. (In Russ.)]

132

Visser K, van der Heijde D. Optimal dosage and rout of administration of methotrexate in rheumatoid arthritis: a systemic review of the literature. Ann Rheum Dis. 2009;68:1094-9. DOI: 10.1136/ard.2008.092668.

133

Mouterde G, Baillet A, Gaujoux-Viala C, et al. Optimizing methotexate therapy in rheumatoid arthritis: a systemic literature review. Joint Bone Spine. 2011;78:587-92. DOI: 10.1016/jjbspin.2011.01.010.

134

Shea B, Swinden MV, Tanjong Ghogomi E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013 May 31;5:CD000951. DOI: 1002/14651858.CD000951.pub2.

135

Braun J, Kastner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008;58:73-81. DOI: 10.1002/art.23144.

136

Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Brit J Rheumatol. 1997;36:86-90. DOI: 10.1093/rheumatology/36.1.86.

137

Rozin A, Scharpira D, Balbir-Gurman A, et al. Relapse of rheumatoid arthritis after substitution of oral for parental administration of methotrexate. Ann Rheum Dis. 2002;61:756-7. DOI: 10.1136/ard.61.8.756.

138

Bingman SJ, Buch MH, Lindsay S, et al. Parental methotrexate should be given before biological therapy. Rheumatology (Oxford). 2003;42:1009-10. DOI: 10.1093/rheumatology/keg246.

139

Wegrzyn J, Adeleine P, Miossec P. Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann Rheum Dis. 2004;63:1232-4. DOI: 10.1136/ard.2003.011593.

140

Moitra RK, Ledingham JM, Hull RG, et al. Caveats to the use of parental methotrexate in the treatment of rheumatic disease. Rheumatology (Oxford). 2005;44:256-7. DOI: ttp://dx.doi.org/10.1093/rheumatology/keh471.

141

Osman A, Mulherin D. Is parental methotrexate worth trying. Ann Rheum Dis. 2001;60:432. DOI: 10.1136/ard.60.4.432.

142

Burbage G, Gupta R, Lim K. Intramuscular methotrexate in inflammatory rheumatic disease. Ann Rheum Dis. 2001;60:1156. DOI: 10.1136/ard.60.12.1156.

143

Linde L, Hetland ML, Ostergaard M. Drug survival and reasons for discontinuation of intramuscular methotrexate: a study of 212 consecutive patients switching from oral methotrexate. Scand J Rheumatol. 2006;35:102-6. DOI: 10.1080/03009740500343294.

144

Bakker MF, Jacobs JWG, Welsing PMJ, et al. Are switching from oral to subcutaneous methotrexate or additional of cyclosporine to methotrexate useful steps in tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study. Ann Rheum Dis. 2010;69:1849-52. DOI: 10.1136/ard.2009.124065.

145

Mainman H, McClaren E, Heycock C, et al. When should we use parental methotrexate? Clin Rheumatol. 2010;29:1093-8. DOI: 10.1007/s10067-010-1500-09.

146

Scott D, Claydon P, Ellis C, Buchan S. A retrospective study of the effect of switching from oral to subcutaneous (SC) methotrexate (MTX): the Methotrexate Evaluation of Norwich Treatment Outcomes in RA (MENTOR) study. Glasgow, UK: British Soc Rheumatology (Oxford); 2012. P. 221.

147

Hazlewood G. Sucutaneous delivery of methotrexate is associated with improved treatment survival compared to oral administration of the initial treatment of patients with early rheumatoid arthritis. Arthritis Rheum. 2013;65(Suppl 10):627.

148

Liakos A, Batley M, Hammond T, et al. Subcutaneous methotrexate is more efficacious and better tolerated than oral methotrexate: the experience of a large group of patients in the Rheumatology department of a district general hospital. Ann Rheum Dis. 2012;71(Suppl 3):672. DOI: 10.1136/annrheumdis-2012-eular.593.

149

Mueller R, Schiff MH, Haile SR, von Kempis J. Effectiveness, tolerability, and safety of subcutaneous methotexate in early rheumatoid arthritis: clinical data from Dt. Gallen cohort. Ann Rheum Dis. 2014;73(Suppl 2). DOI: 10.1136/annrheumdis-2014-eular.2031.

150

Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomized, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at dose ≥15 mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014;73:1549-51. DOI: 10.1136/annrheumdis-2014-205228.

151

Fitzpatric R, Scott DG, Keary I. Cost-minimization analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who had have an insufficient response or intolerance to oral methotrexate. Clin Rheumatol. 2013;32:1605-12. DOI: 10.1007/s10067-013-2318-z.

152

Van der Heijde DM, van Riel PL, Gribnau FW, et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet. 1989;333:1036-8. DOI: 10.1016/S0140-6736(89)92442-2.

153

Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomized, multicenter trial. Lancet. 1999;353:259-66. DOI: 10.1016/S0140-6736(98)09403-3.

154

Sharp JT, Strand V, Leung H, et al. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis. Results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum. 2000;43:495-505. DOI: 10.1002/1529-0131(200003)43:3%3C495::AID-ANR4%http://3E3.0.CO;2-U.

155

Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Int Med. 1999;159:2542-50. DOI: 10.1001/archinte.159.21.2542.

156

Dougados M, Combe B, Cantagrel A, et al. Combination therapy in early rheumatoid arthritis: a randomized, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis. 1999;58:220-5. DOI: 10.1136/ard.58.4.220.

157

Kavanaugh A, Wells AF. Benefits and risk of low-dose glucocorticoid treatment in the patients with rheumatoid arthritis. Rheumatology (Oxford). 2014. DOI: 10.1093/Rheumatology/keu135.

158

Caporali R, Scire CA, Todoerti M, Montecucco C. The role of low-dose glucocorticoids for rheumatoid arthritis in the biologic era. Clin Exp Rheumatol. 2013;31(Suppl 78):S9-13.

159

Roubille C, Richer V, Starnino T. The effects of the TNF inhibitors, methotrexate, NSAIDS and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systemic review and meta-analysis. Ann Rheum Dis. 2014;73 (Suppl 2) [P0169].

160

Dernis E, Ruyssen-Wtrand A, Mouterde C, et al. Use of glucocorticoids in rheumatoid arthritis - practical modalities based on data from literature and expert opinion. Join Bone Spain. 2010;77:451-7. DOI: 10.1016/j.jbspin.2009.12.010.

161

Ma MHY, Kingsley GH, Scott DL. A systemic comparison of combination DMARD therapy and tumor necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2010;49:91-8. DOI: 10.1093/Rheumatology(Oxford)/kep331.

162

Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systemic review and meta-analysis of efficacy and safety. BMC Musculoskeletal Dis. 2008;9:52. DOI: 10.1186/1471-2474-9-52.

163

Aaltonen KJ, Vikki LM, Malmiaara A, et al. Systemic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in the treatment of rheumatoid arthritis. PLoS ONE. 2012;7:e30275. DOI: 10.1371/journal.pone.0030275.

164

Nixon RM, Bansback N, Brennan A. Using mixed treatment comparison and meta-regression to perform indirect comparisons to estimate efficacy of biologic treatment in rheumatoid arthritis. Stat Med. 2007;26:1237-54. DOI: 10.1002/sim.2624.

165

Schmitz S, Adams R, Walsh CD, et al. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrated differences between treatments: a Bayesian approach. Ann Rheum Dis. 2012;71:225-30. DOI: 10.1136/ard.2011.200228.

166

Gartlehner G, Hansen RA, Jonas BL, et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systemic review and meta-analysis. J Rheumatol. 2006;33(12):2398-407.

167

Kristensen LE, Christensen R, Biddal H, et al. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systemic literature review. Scand J Rheumatol. 2007;36:411-7. DOI: 10.1080/03009740701607067.

168

Wiens A, Venson R, Pharm D, et al. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy. 2010;30:339-53. DOI: 10.1592/phco.30.4.339.

169

Schmitz S, Adams R, Walsh C, et al. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. Ann Rheum Dis. 2012;71:225-30. DOI: DOI: 10.1136/annrheumdis-2011-200228.

170

Singh JA, Christensen R, Wells GA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007848. DOI: 10.1002/14651858.CD007848.pub2

171

Salliot C, Finckh A, Katchamart W, et al. Indirect comparisons of the efficacy of biological anti-rheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumor necrosis factor agents: a meta-analysis. Ann Rheum Dis. 2011;70:266-71. DOI: 10.1136/ard.2010.132134.

172

Bergman GJ, Hochberg MC, Boers M, et al. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum. 2010;39:425-41. DOI: 10.1016/j.semarthrit.2009.12.002.

173

Kristensen LE, Jakobsen AK, Bartels EM, et al. The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systemic quantitative review of randomized controlled trials. Scand J Rheumatol. 2011;40:1-7. DOI: 10.3109/03009742.2010.491834.

174

Devine EB, Alfonso-Cristanchp R, Sullivan SD. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparison approach. Pharmacotherapy. 2011;31:39-51. DOI: 10.1592/phco.31.1.39.

175

Roy S, Cifaldi MA. Number needed to treat for biologic therapies in patients with active rheumatoid arthritis despite methotrexate: a mixed treatment comparison meta-analysis. Ann Rheum Dis. 2011;70(Suppl 3):432.

176

Gallego-Galisteo M, Villa-Rubio A, Alergre-del Rau E, et al. Indirect comparison of biological treatments in refractory rheumatoid arthritis. J Clin Pharm Ther. 2012;37:301-7. DOI: 10.1111/j.1365-2710.2011.01292.x.

177

Guyot P, Taylor P, Christensen R, et al. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis. Arthritis Res Ther. 2011;13:R204. DOI: 10.1186/ar3537.

178

Turksta E, Ng S-K, Scuffham PA. A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis. Curr Med Res Opin. 2011;27:1885-97. DOI: 10.1185/03007995.2011.608655.

179

Mandema JW, Salinger DH, Baumgartner SW, Gibbs MA. A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis. Clin Pharmacol Ther. 2011;90:828-35. DOI: 10.1038/clpt.2011.256.

180

Favalli EG, Pregnolato F, Biggioggero M, Meroni PL. The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trials. Ther Adv Musculoskeletal Dis. 2012;4:213-23. DOI: 10.1177/1759720X12449082.

181

Pierreisnard A, Issa N, Barnetche T, et al. Meta-analysis of clinical and radiological efficacy of biologics in rheumatoid arthritis patients naive or inadequately responsive to methotrexate. Join Bone Spain. 2013;80:386-93. DOI: 10.1016/j.jbspin.2012.09.03.

182

Jones G, Darian-Smith E, Kwok M, Winzenberg T. Effect of biologic therapy on radiologic progression in rheumatoid arthritis: what does it add to methotrexate? Biologics. 2012;6:155-61.

183

Weinblatt ME, Schiff M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013;65:28-38. DOI: 10.1002/art.37711.

184

Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: a systemic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;17:2275-85. DOI: 10.1001/jama.295.19.2275.

185

Leombruno JP, Einarson TR, Keystone EC. The safety of antitumor necrosis factor treatments in rheumatoid arthritis: meta and exposure adjusted pooled analysis of serious adverse events. Ann Rheum Dis. 2009;68:1136-45. DOI: 10.1136/ard.2008.091025.

186

Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview (Review). Cochrane Database Syst Rev. 2011 Feb 16;(2):CD008794. DOI: 10.1002/14651858.CD008794.pub2.

187

Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview (Review). Cochrane Database Syst Rev. 2012;3.

188

Fautrel B, Pham T, Mouterde G, et al. Recommendations of the French Society for Rheumatology (Oxford) regarding TNF alpha antagonist therapy in patients with rheumatoid arthritis. Joint Bone Spine. 2007;74:627-37. DOI: DOI: 10.1016/j.jbspin.2007.10.001.

189

Caporali R, Conti F, Aliverini S, et al. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology (Oxford). I Efficacy. Clin Exp Rheumatol. 2011;29(Suppl 66):S7-14.

190

Deighton C, Hyrich K, Ding T, et al. BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology (Oxford). 2010;49:1197-9. DOI: 10.1093/rheumatology/keq006a.

191

Goeb V, Ardizzone M, Arnaud L, et al.; Club Rhumatismes at Inflammations (CRI). Recommendations for using TNFα antagonists and French clinical practice guidelines endorsed by French National Authority for health. Join Bone Spain. 2013;80:574-81. DOI: 10.1016/j.jspin.2013.09.001.

192

Smolen JS, Schoels MM, Nishimoto N, et al. Consensus state on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis. 2013;72:482-92. DOI: 10.1136/annrheumdis-2012-202469.

193

Malavia AP, Ledingham J, Bloxham J, et al.; BSR Clinical Affairs Committee and Standards, audit and Guidelines Working Group, the BHPR. The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis. Rheumatology (Oxford). 2014. DOI: 10.1093/Rheumatology/ker168.

194

Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of Rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:909-20. DOI: 10.1136/annrheumdis.-2010-144998.

195

Bukhari M, Abernethy R, Deighton C, et al. BSR and BHPR guidelines on the use of Rituximab in rheumatoid arthritis. Rheumatology (Oxford). 2011;50:2311-3. DOI: 10.1093/Rheumatology/ker106a.

196

Bathon JM, Martin RW, Fleischmann RM, et al. Comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343:1586-93. DOI: 10.1056/NEJM200011303432201.

197

Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two year radiographic and clinical outcome. Arthritis Rheum. 2002;46:1443-50. DOI: 10.1002/art.10308.

198

Burmester GR, Kivitz AJ, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomized CONCERTO trial. Ann Rheum Dis. 2014. DOI: 10.1136/annrheumdis-2013-204769.

199

Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012;71:1914-5. DOI: 10.1136/annrheumdis-2012-201544.

200

Pope JE, Haraoui B, Thorne JT, et al. The Canadian Methotrexate and Etanercept Outcome Study: a randomized trial of discontinuation methotrexate after 6 months or etanercept and methotrexate therapy in rheumatoid arthritis. Ann Rheum Dis. 2013. DOI: 10.1136/annrheumdis-2013-203684.

201

Kameda H, Kanbe K, Sato E, et al. Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from JESMR study. J Rheumatol. 2011;38:1585-92. DOI: 10.3899/jrheum.110014.

202

Hyrich KL, Symmons DP, Watson KD, et al. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or anather diseasemodifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatolofy Biologics Register. Arthritis Rheum. 2006;54:1786-95. DOI: 10.1002/art.21830.

203

Kristensen LE, Kapetanovic MC, Gulfe A, et al. Predictors of response to anti-TNF therapy according to AR and EULAR criteria in patients with established RA: results from South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford). 2008;47:495-99. DOI: 10.1093/Rheumatology(Oxford)/ken002.

204

Kristensen LE, Saxne T, Nilsson JA, Geborec P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from six-year observational study in South Sweden. Artritis Res Ther. 2006;8(6):R174

205

Hertland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveilance of clinical practice in the natiowide Danish DANBIO registry. Arthritis Rheum. 2010;62:22-32. DOI: 10.1002/art.27227.

206

Iannone F, Gremese E, Atzeni F, et al. Long-term retention of tumor necrosis factor-alpha inhibitor therapy in large Italian cohort of patients with rheumatoid arthritis from GISEA registry: an appraisal of predictors. J Rheumatol. 2012;39:1179-84. DOI: 10.3899/jrheum.111125.

207

Aga A-B, Lie E, Uhling T, et al. Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010. Ann Rheum Dis. 2013. DOI: 10.1136/annrheumdis-2013-204020.

208

Soliman MM, Ashcroft DM, Watson KD, et al. Impact of concomitant use of DMARDs on the ersistence with anti- TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology (Oxford) Biologics Register. Ann Rheum Dis. 2011;70:583-9. DOI: 10.1136/ard.2010.139774.

209

Blum MA, Koo D, Doshi JA. Measurement and rates of persistence with adherence to biologics for rheumatoid arthritis: a systemic review. Clin Ther. 2011;33:901-3. DOI: 10/1016/j.clinthera.2011.06.001.

210

Takeuchi T, Kaneko Y, Atsumi T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in RA patients with inadequate response to methotrexate: 24-week results from a randomized controlled study (SURPRISE study). Ann Rheum Dis. 2013;72(Suppl 3):62.

211

Kojima T, Yabe Y, Kaneko A, et al. Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study. Rheumatology (Oxford). 2014. DOI: 10.1093/Rheumatology(Oxford)/key/302.

212

Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis. 2010;69:88-96. DOI: 10.1136/ard.2008.105197.

213

Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, doubleblind, controlled phase 4 trial. Lancet. 2013;381:1541-50. DOI: 10.1016/S0140-6736(13)60250-0.

214

Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013;72:43-50. DOI: 10.1136/annrheumdis-2011-201282.

215

Dougados M, Kissel K, Conaghan PG, et al. Clinical, radiographic and immunogenetic effects after 1 year of tocilisumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis. 2014;73:803-9. DOI: 10.1136/annrheumdis-2013-204761.

216

Schoels MM, van der Heijde D, Breedveld FC, et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systemic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis. 2013;72:583-9. DOI: 10.1136/annrheumdis-012-202470.

217

Jansen JP, Buckley F, Dejonckheere F, Ogale S. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patients reported outcome (PROs) in rheumatoid arthritis patients with an inadequate to conventional DMARDs - a systemic review and network meta-analysis. Health Quality Life Outcome. 2014;12:102. DOI: 10.1186/1477-7525-12-102.

218

Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-806. DOI: 10.1002/art.22025.

219

Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353:1114-23. DOI: 10.1136/ard.2007.074773.

220

Genovese MC, Schiff M, Luggen M, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy. Ann Rheum Dis. 2008;67:547-54. DOI: 10.1136/ard.2007.074773.

221

Emery P, Keystone E, Tony H-P, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicenter randomized placebo-controlled trial. Ann Rheum Dis. 2008;67:1516-23. DOI: 10.1136/ard.2008.092932.

222

Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor alpha inhibitors (GO-AFTER study): a multicenter, randomized, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374:210-21. DOI: 10.1016/S0140-6736(09)60506-7.

223

Buch MH, Bingham SJ, Bejarano V, et al. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. Arthritis Rheum. 2007;57:448-53. DOI: 10.1002/art.22617.

224

Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther. 2006;8:R29. DOI: 10.1186/ar1881.

225

Wick MC, Ernestam S, Lindblad S, et al. Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol. 2005;34:353-8. DOI: 10.1080/03009740510026887.

226

Gomez-Reino JJ, Maneiro JR, Ruiz J, et al. Comparative effectiveness of switching to alternative tumor necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study. Ann Rheum Dis. 2012;71:1861-4. DOI: 10.1136/annrheumdis-2012-201324.

227

Burmester GR, Kary S, Unnebrink K, et al. Treatment of rheumatoid arthritis with adalimumab is effective for patients ith and without history of other anti-TNF therapies.Rheumatology (Oxford). 2010;49(Suppl 1):i89-111.

228

Virkki LM, Valleala H, Takakubo Y, et al. Outcomes of switching anti-TNF drugs in rheumatoid arthritis - a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN). Clin Rheumatol. 2011;30:1447-54. DOI: 10.1007/s10067-011-1779-1.

229

Chatzidionysiou K, Askling J, Eriksson J, et al.; ARTIS group. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Ann Rheum Dis. 2014. DOI: 10.1136/annrheumdis-2013-204714.

230

Lloyd S, Bujkiewicz S, Wailoo AJ, et al. The effectiveness of anti-TNF-α therapies when used sequential in rheumatoid arthritis patients: a systemic review and meta-analysis. Rheumatology (Oxford). 2010;49:2313-21. DOI: 10.1093/Rheumatology(Oxford) keq169.

231

Rendas-Baum R, Wallenstein GV, Koncz T, et al. Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis with inadequate response to tumor necrosis factoralpha inhibitors. Arthritis Res Ther. 2011;13:R25. DOI: 10.1186/ar3249.

232

Schoels M, Aletaha D, Smolen JS, Wong JB. Comparative effectiveness and safety of biological treatment options after tumor necrosis factor inhibitor failure in rheumatoid arthritis: systemic review and indirect pair wise meta-analysis. Ann Rheum Dis. 2012;71:1303-8. DOI: 10.1136/annrheumdis-2011-200490.

233

Remy A, Avouac J, Gossec L, et al. Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. Clin Exp Rheumatol. 2011;29:96-103. 233. NICE. Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: final appraisal determination. Available from: http://guidance.nice.org.uk/TA/WaveR/61/FAD/FinalAppraisalDetermination/pdf

234

Malottki K, Barton P, Tsourapas A, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after failure of a tumor necrosis factor inhibitor: a syreview and economic evaluation. Health Technol Assess. 2011;15(4):1-278.

235

Moots RJ, Naisbett-Groet B. The efficacy of biologic agents in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitors: a systemic review. Rheumatology (Oxford). 2012;51:2252-61. DOI: 10.1093/Rheumatology(Oxford)/kes217.

236

Finckh A, Ciurea A, Brulhart L, et al.; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum. 2007;56:1417-23. DOI: 10.1002/art.22520.

237

Finckh A, Ciurea A, Brulhart L, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumor necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis. 2010;69:387-93. DOI: 10.1136/ard.2008.105064.

238

Soliman MM, Hyrich KL, Lunt M, et al. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology (Oxford) Biologics Register. Arthritis Care Res (Hoboken). 2012;64:1108-15.

239

Solau-Gervais E, Prudhomme C, Philippe P, et al. Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure. Joint Bone Spine. 2012;79:281-4. DOI:

240

DOI: 10.1016/j.jbspin.2011.05.002.

241

Emery P, Gottenberg JE, Rubbert-Roth A, et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis. 2014. DOI: 10.1136/annrheumdis-2013-203993.

242

Насонов ЕЛ. Применение ритуксимаба при ревматоидном артрите. В кн: Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Под ред. Е.Л. Насонова. Москва: ИМА-ПРЕСС; 2011. C. 55-93. [Nasonov EL. Application rituksimab at rheumatoid arthritis. In: Anti-B-kletochnaya terapiya v revmatologii: fokus na rituksimab [Anti-B-cellular therapy in rheumatology: focus on rituksimab]. Nasonov EL, editor. Moscow: IMA-PRESS; 2011. P. 55-93.]

243

Van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508-19. DOI: 10.1056/NEJMoa1112072.

244

Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495-507. DOI: 10.1056/NEJMoa1109071.

245

Van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis on methotrexate: 12-month data from a 24-month phase 3 randomized radiographic study. Arthritis Rheum. 2013;65:559-70. DOI: 10.1002/art.37816.

246

Lee EB, Fleischmann RM, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. New Engl J Med. 2014;370:2377-86. DOI: 10.1056/NEJMoa1310476.

247

Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a randomized phase 3 trial. Lancet. 2013;381:451-60. DOI: 10.1016/S0140-6736(12)61424-X.

248

Kawalec P, Mikrut A, Wisniewska N, Pilc A. The effectiveness of tofacitinib, a novel Janus kinase inhibitor. In the treatment of rheumatoid arthritis: a systemic review and meta-analysis. Clin Rheumatol. 2013;32:1414-24. DOI: 10.1007/s10067-013-2329-9.

249

Berhan A. Efficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying antirheumatic drugs: a meta-analysis of randomized double-blind controlled studies. BMC Musculoskeletal Disorders. 2103;14:332. DOI: 10.1186/1471-2474-14-332.

250

Vieira MC, Wallenstein G, Bradley J, et al. Tofacitinib versus biologic treatments in patients with active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor inhibitors - a network meta-analysis. Ann Rheum Dis. 2014;72(Suppl 3):619. DOI: 10.1136/annrheumdis-2013-eular.1841.

251

Bredermeier M, de Oliveira FK, Rocha CM. Low-versus highdose rituximab for rheumatoid arthritis: a systemic review and meta-analysis. Arthritis Care Res. 2014;66:228-35. DOI: 10.1002/acr.22116.

252

Klarenbeek NB, van der Kooij SM, Guler-Yuksel M, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: expletory analysis from the BeST study. Ann Rheum Dis. 2011;70:315-9. DOI: 10.1136/ard.2010.136556.

253

Van der Maas A, Kievit W, van der Bemt BJF, et al. Downtitration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis. 2012:71:1849-54. DOI: 10.1136/annrheumdis-2011-200945.

254

Tanaka Y, Hirata S, Kubo S, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis. 2013. DOI: 10.1136/annrheumdis-3013-204016.

255

Chatzidionysiou K, Turesson C, Teleman A, et al. A multicenter, randomized, controlled, open-label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients in stable clinical remission. Arthritis Rheum. 2012;64(Suppl):S336.

256

Hariga M, Takeuchi T, Tanaka Y, et al. Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Mod Rheumatol. 2012;22(6):814-22. DOI: 10.3109/s10165-011-0586-5.

257

Kavanaugh A, Emery P, Felischmann RM, et al. Withdrawal of adalimumab in early rheumatoid arthritis patients who attained stable low disease activity with adalimumab plus methotrexate: results of a phase 4, double-blind, placebo-controlled trial. Rheumatology (Oxford). 2012;51(Suppl 3):iii27.

258

Fautrel B, Gandjbakhch F, Foltz V, et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step-down strategy trial based on progressive spacing of TNF-blocker injections (STRASS trial). Ann Rheum Dis. 2013;2(Suppl 3):72. DOI: 10.1136/annrheumdis-2013-eular.271.

259

Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomized controlled trial. Lancet. 2013;381:918-29. DOI: 10/1016/S0140-6736(12)61811-X.

260

Smolen JS, Emery P, Fleischmann R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomized controlled OPTIMA trial. Lancet. 2014;383:321-32. DOI: 10.1016/S010-673(13)61751-1.

261

Horslev-Petersen K, Hertland ML, Junker P, et al. Very high rates are achieved by methotrexate and intraarticular glucocorticoids independent of induction therapy with adalimumab; year 2 clinical results of an investigator-initiated randomized, controlled clinical trial of early, rheumatoid arthritis (OPERA). Arthritis Rheum. 2013;65 (Suppl):S1148.

262

Emery P, Hamouden M, FitzGerald M, et al. Induction of remission in patients with up to 12 months of moderate-tosevere rheumatoid arthritis symptoms treated with etanercept plus methotrexate over 52 weeks. Arthritis Rheum. 2012;64 (Suppl):S1077.

263

Emery P, Hammoudeh M, Fitzgerald O, et al. Assessing maintenance of remission with reduced dose etanercept plus methotrexate, methotrexate alone, or placebo in patients with early rheumatoid arthritis who achieved remission with etanercept and methotrexate: the PRIZE study. Ann Rheum Dis. 2013;72(Suppl 3):399.

264

Nampei A, Nagayama Y. Discontinuation of tocilizumab after attaining remission in patients with rheumatoid arthritis. Ann Rheum Dis. 2013;72(Suppl 3):877. DOI: 10.1136/annrheumdis-2013-eular.2618.

265

Aguilar-Lozano L, Castillo-Ortiz JD, Vargas-Serafin C, et al. Sustained clinical remission and rate of relapse after tocilizumab withdrawal in patients with rheumatoid arthritis. J Rheumatol. 2013;40:1069-73. DOI: 10.3899/jrheum.121427.

266

Durez P, Depresseux G, Nzeusseu Toukar A, et al. Rate or remission by tocilizumab or methotrexate induction therapy in early active rheumatoid arthritis: results of the TOMERS trial. Ann Rheum Dis. 2013;72(Suppl 3):623. DOI: 10.1136/annrheumdis-2013-eular.1852.

267

Takeuchi T, Matsubara T, Ohta S, et al. Abatacept biologicfree remission study in established rheumatoid arthritis - ORION study. Ann Rheum Dis. 2013;72(Suppl 3):613. DOI: 10.1136/annrheumdis-2013-eular.1826.

268

Batticciotto A, Varisco V, Antivalle M, et al. Dose reduction in patients with rheumatoid arthritis responding to the standard rituximab regimen. Ann Rheum Dis. 2013;72(Suppl l):877. DOI: 10.1136/annrheumdis-2013-eular.2619.

269

O’Mahony R, Richards A, Deighton C, Scott D. Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systemic review and meta-analysis. Ann Rheum Dis. 2010;69:1823-6. DOI: 10.1136/ard.2008.105577.

270

Ten Wolde S, Breedveld FC, Hermans J, et al. Randomized placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet. 1996;347:347-52. DOI: 10.1016/S0140-6736(96)90535-8.

271

Ten Wolde S, Hermans J, Breedvald FC, Dijkmans BA. Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuation. Ann Rheum Dis. 1997;56:235-9. DOI: 10.1136/ard.56.4.235.

272

Van der Woude D, Visser K, Klarenbeek NB, et al. Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies. Rheumatology (Oxford). 2012;51:1120-8. DOI: 10.1093/rheumatology/ker516.

273

Gonzalez A, Maradit KH, Crowson CS, et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis. 2008;67:64-9. DOI: 10.1136/ard.2006.059980.

274

Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692-701. DOI: 10.1002/art.21675.

275

Попкова ТВ, Герасимова ЕВ, Новикова ДС, Насонов ЕЛ. Метотрексат и риск сердечно-сосудистых осложнений при ревматоидном артрите. Научно-практическая ревматология. 2012;50(6):70-9. [Popkova TV, Gerasimova EV, Novikova DS, Nasonov EL. Methotrexate and cardiovascular risk in rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;50(6):70-9. (In Russ.)]. DOI: 10.14412/1995-4484-2012-1297.

276

Wasco MCM, Dasgupta A, Hubert H, et al. Propensity-adjusted assoсiation of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum. 2013;65:334-42. DOI: 10.1002/art.37723.

277

Dixon WG, Watson KD, Lunt M, Hyrich KL; British Society for Rheumatologic register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from British Society for Rheumatology (Oxford) Biologics Register. Arthritis Rheum. 2007;56:2905-91. DOI: 10.1002/art.22809.

278

Westlake SL, Colebatch AN, Baird J, et al. Tumоr necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2011;50:518-31. DOI: 10.1093/rheumatology/keq316.

279

Del Rincon I, Battafarano DF, Restrepo JF, et al. Glucocorticoid dose trashholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum. 2013. DOI 10.1002/art.38210.

280

Pereira IA, da Mota LMH, Cruz BA, et al. 2012 Brazilian Society of Rheumatology (Oxford) Consensus on the management of comorbidities in patients with rheumatoid arthritis. Rev Bras Reumatol. 2012;52:474-95.

281

Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69:325-31. DOI: 10.1136/ard.2009.113696.

282

Насонов ЕЛ, Каратеев ДЕ, Чичасова НВ. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место метотрексата. Научно-практическая ревматология. 2014;52(1):8-26. [Nasonov EL, Karateev DE, Chichasova NV. New recommendations for the management of rheumatoid arthritis (EULAR, 2013): the role of methotrexate. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(1):8-26. (In Russ.)]. DOI: 10.14412/1995-4484-2014-8-26.

283

Pincus T, Kathryn A, Gibson MD, Castrejon I. Update on methotrexate as the anchor drug for rheumatoid arthritis. Bull Hosp Joint Dis. 2013;71 (Suppl 1):S9-19.

284

McLean-Tooke A, Aldridge C, Waugh A, et al. Methotrexate, rheumatoid arthritis and infection risk - what is the evidence? Rheumatology (Oxford). 2009;48:867-71. DOI: 10.1093/rheumatology/kep101.

285

Bourre-Tessier J, Haraou B. Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systemic review. J Rheumatology (Oxford). 2010;37:1416-21. DOI: 10.3899/jrheum.090153.

286

287

Dougados MR, van der Heijde DM, Brault Y, et al. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: finding from a randomized study (COMET). J Rheumatol. 2014. DOI: 10.3899/jrheum.131238.

288

Curtis JR, Zhang J, Xie F, et al. Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States. Arthritis Care Res. 2014. DOI: 10.1002/acr.22383.

289

Alsaeedi S, Keystone EC. Oral or subcutaneous methotrexate for rheumatoid arthritis. Nat Rev Rheumatol. 2014. DOI: 10.1038/nrreum.2014.129.

290

Strand V, Williams S, Miller PSJ, et al. Discontinuation of biologic therapy in rheumatoid arthritis (RA): analysis from the Consortium of Rheumatology (Oxford) Researchers of North America (CORRONA) database. Ann Rheum Dis. 2013;72(Suppl 3):71.

291

Asai S, Kojima T, Oguchi T, et al. OP0069 Concomitant methotrexate affect the incidence of large joint replacement surgery in the rheumatoid arthritis patients treated with etanercept. Ann Rheum Dis. 2014;73:86-87. DOI: 10.1136/annrheumdis-2014-eular.1502.

292

Rezaei H, Saevarsdottir S, Forslind K, et al. The early rheumatoid arthritis patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responder’s population in the SWEFOT trial. Ann Rheum Dis. 2012;71:186-91. DOI: 10.1136/annrheumdis-2011-200038.

293

Gaujoux-Viala C, Mitrovic S, Barnetche T, et al. THU0116 Efficacy of glucocorticoids for early rheumatoid arthritis (RA): a meta-analysis of randomized controlled trials. Ann Rheum Dis. 2014;73:218. DOI: 10.1136/annrheumdis-2014-eular.5840.

294

Verschueren P, de Cock D, Corluy L, et al. THU0137 Associated with a glucocorticoid bridging scheme, methotrexate is as effective alone as in combination with other DMARDs for early rheumatoid arthritis, with fewer reported side effects: 16 weeks remission induction data from the CARERA trial. Ann Rheum Dis. 2014;73:226. DOI: 10.1136/annrheumdis-2014-eular.2137.

295

Насонов ЕЛ. Новые подходы к фармакотерапии ревматоидного артрита: тофацитиниб. Научно- практическая ревматология. 2014;52(2):209-21. [Nasonov EL. New approaches to pharmacotherapy of rheumatoid arthritis: tofacitinib. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(2):209-21. (In Russ.)]. DOI: 10.14412/1995-4484-2014-209-221.

296

European Medical Agency. Xeljanz. 2013; accessed 25 May, 2014) Available from: http://www.ema.europa.eu/ema/indexjsp?curl=pages/medicines/human/medicines/002542/smops/Negative/human_smop_000501jsp&mid=WC0b01ac058001d127

297

Committee for Medicinal Products for Human Use (CHMP). Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP). 22-25 July 2013. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_a nd_events/news/2013/07/news_detail_001851.jsp&mid=WC0 b01ac058004d5c1.

298

Pfizer. Pfizer Receives CHMP Negative Opinion Regarding Marketing Authorization In Europe For Rheumatoid Arthritis Treatment XELJANZ (tofacitinib citrate). 2013; accessed 25 May 2013. Available from: http://press.pfizer.com/pressrelease pfizer-receives-chmp-negative-opinion-regardingmarketing-authorization-europe-rheumat

299

Salgado E, Maneiro JR, Carmona L, Gomez-Reino JJ. Safety profile of protein kinase inhibitors in rheumatoid arthritis: systemic review and meta-analysis. Ann Rheum Dis. 2013, April 18. DOI: 10.1136/annrheumdis-2012-203116.

300

Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA. 2013;309:887-95. DOI: 10.1001/jama.2013.1099.

The authors declare that there are no conflicts of interest present.